Cadrenal Therapeutics, Inc. Common Stock Stock Analysis & AI Score
Cadrenal Therapeutics, Inc. Common Stock (CVKD) has an ST Score of 40.9 (C), driven by its Forecast (A) and held back by its Momentum (F). Analysts rate it Buy with a $32.00 price target (+3109.6% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AICVKD Stock Price History
CVKD Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
CVKD Latest Stock News
ST Score
Cadrenal Therapeutics, Inc. Common Stock (CVKD) has an ST Score of 40.9 (C), driven by its Forecast (A) and held back by its Momentum (F). Analysts rate it Buy with a $32.00 price target (+3109.6% upside).
- Strongest
- ForecastA
- Weakest
- MomentumF
All factor grades
- ForecastA
- GrowthB+
- ValuationB-
- Financial StrengthB-
- ProfitabilityF
- MomentumF
- Piotroski2/9
Press Releases
Company Contact Details
CVKD stock: frequently asked questions
What is CVKD's ST Score?
Cadrenal Therapeutics, Inc. Common Stock (CVKD) has an ST Score of 40.9 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CVKD a buy, hold, or sell?
Analysts rate CVKD a Buy, with a price target of $32.00 (+3109.6% vs the current price). Our ST Score grades it C (40.9/100). The ST Score is a data-driven signal, not a recommendation.
What are CVKD's factor grades?
Valuation B-, Profitability F, Financial Strength B-, Momentum F, Growth B+, Forecast A.
What is CVKD's valuation grade?
Cadrenal Therapeutics, Inc. Common Stock (CVKD) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CVKD's growth grade?
Cadrenal Therapeutics, Inc. Common Stock (CVKD) earns a growth grade of B+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CVKD's profitability grade?
Cadrenal Therapeutics, Inc. Common Stock (CVKD) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CVKD's financial strength grade?
Cadrenal Therapeutics, Inc. Common Stock (CVKD) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CVKD?
The average analyst price target for Cadrenal Therapeutics, Inc. Common Stock (CVKD) is $32.00 from 1 analysts, which is +3109.6% versus the recent price of $1.00.
What is CVKD's Piotroski score?
Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.